AKUS:NSD-Akouos, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 13.15

Change

+0.12 (+0.92)%

Market Cap

USD 0.45B

Volume

0.10M

Average Target Price

USD 22.50 (+71.10%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+4.63 (+2.34%)

USD79.44B 132.60 106.34
REGN Regeneron Pharmaceuticals, Inc

+12.43 (+2.37%)

USD55.78B 14.90 11.77
BNTX BioNTech SE

+10.35 (+5.08%)

USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

+0.87 (+0.46%)

USD48.53B 17.87 12.86
ALXN Alexion Pharmaceuticals, Inc

-0.58 (-0.32%)

USD39.90B 58.60 42.42
BGNE BeiGene, Ltd

-4.17 (-1.25%)

USD31.22B N/A N/A
GMAB Genmab A/S

-1.04 (-2.33%)

USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.06 (+1.36%)

USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

+0.52 (+1.19%)

USD26.73B 22.60 15.75
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AKUS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.69% 13% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.69% 13% F 6% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.45B 52% F 47% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 94% A
Price/Book Ratio 1.56 89% B+ 73% C
Price / Cash Flow Ratio -11.01 58% F 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -26.00% 79% C+ 33% F
Return on Invested Capital -35.19% 64% D 22% F
Return on Assets -14.25% 76% C 23% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 16.83 6% F 2% F
Short Percent 11.11% 26% F 17% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.